Re: Still waiting for that BETonMACE CKD sub-study 7 months later
in response to
by
posted on
Jun 12, 2020 01:43PM
The NIH spends more on CVS than Cancer. https://report.nih.gov/categorical_spending.aspx
IMHO it is likely that if we get a deal it will with one of thes SGLT2 or DPP4 comanies as results in terms of MACE and CHF pevention are confined to certain drugs and if this combination proves superior it will help sales in a very competitive market. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959222/
I would imagine in this highr risk group of pateints with a better designed trial quantifiable results should be obtainable in a years time.